Journal
FRONTIERS IN PHYSIOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2021.749770
Keywords
lipids; flavivirus; antivirals; cholesterol; fatty acids; statins; metformin
Categories
Funding
- National Council of Science and Technology of Mexico (CONACYT) [220824]
- CONACYT
Ask authors/readers for more resources
Host lipid metabolism plays a crucial role in controlling flavivirus infections, with FDA-approved hypolipidemic drugs potentially serving as alternative treatments. Further understanding of the regulation between host lipid metabolism and signaling pathways triggered during infections is needed to explore the potential of lipid-lowering drugs as safe host-targeted antivirals.
Although Flaviviruses such as dengue (DENV) and zika (ZIKV) virus are important human pathogens, an effective vaccine or antiviral treatment against them is not available. Hence, the search for new strategies to control flavivirus infections is essential. Several studies have shown that the host lipid metabolism could be an antiviral target because cholesterol and other lipids are required during the replicative cycle of different Flaviviridae family members. FDA-approved drugs with hypolipidemic effects could be an alternative for treating flavivirus infections. However, a better understanding of the regulation between host lipid metabolism and signaling pathways triggered during these infections is required. The metabolic pathways related to lipid metabolism modified during DENV and ZIKV infection are analyzed in this review. Additionally, the role of lipid-lowering drugs as safe host-targeted antivirals is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available